^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MP0310

    i
    Other names: MP0310, MP 0310, AMG 506, alpha-4-1BB
    Associations

    News

    Trials
    Company:
    BeiGene, Molecular Partners
    Drug class:
    CD137 agonist, FAP inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=38, Completed, Molecular Partners AG | Active, not recruiting --> Completed
    Trial completion
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    MP0310
    over1year
    Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=38, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | N=58 --> 38
    Enrollment closed • Enrollment change
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    MP0310
    over2years
    Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=58, Recruiting, Molecular Partners AG | Trial primary completion date: Oct 2021 --> Jul 2022
    Clinical • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    MP0310
    almost3years
    Study to Investigate the Safety, Blood Levels and Activity of MP0310 (AMG 506) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=58, Recruiting, Molecular Partners AG | Trial completion date: Apr 2023 --> Dec 2022 | Trial primary completion date: Apr 2021 --> Oct 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    MP0310
    almost4years
    [VIRTUAL] Selection of first-in-human clinical dose range for the tumor-targeted 4-1BB agonist MP0310 (AMG 506) using a pharmacokinetic/pharmacodynamics modeling approach (AACR-II 2020)
    It provides a rationale for selecting the maximum tested dose, and may help reduce the number of cancer patients receiving sub-therapeutic doses. MP0310 (AMG 506) is currently being evaluated in a Ph1 clinical study.
    Clinical • P1 data • PK/PD data
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • FAP (Fibroblast activation protein, alpha)
    |
    MP0310